Ultragenyx Reports Third Quarter 2018 Financial Results and Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Ultragenyx Pharma (RARE) Tops Q3 EPS by 22c, Revenues Beat
November 5, 2018 4:41 PM ESTUltragenyx Pharma (NASDAQ: RARE) reported Q3 EPS of ($1.74), $0.22 better than the analyst estimate of ($1.96). Revenue for the quarter came in at $11.8 million versus the consensus estimate of $11.1 million.
Were encouraged by the growing demand for Crysvita from both children and... More
